Patents Assigned to Replicor, Inc.
-
Patent number: 9616083Abstract: It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate complexes.Type: GrantFiled: May 17, 2013Date of Patent: April 11, 2017Assignee: REPLICOR INCInventors: Michel Bazinet, Andrew Vaillant
-
Patent number: 9603865Abstract: It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatitis delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.Type: GrantFiled: July 8, 2015Date of Patent: March 28, 2017Assignee: REPLICOR INC.Inventor: Andrew Vaillant
-
Patent number: 9533003Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.Type: GrantFiled: September 15, 2015Date of Patent: January 3, 2017Assignee: REPLICOR INC.Inventors: Michel Bazinet, Andrew Vaillant
-
Patent number: 9492506Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.Type: GrantFiled: May 17, 2013Date of Patent: November 15, 2016Assignee: REPLICOR INC.Inventors: Michel Bazinet, Andrew Vaillant
-
Patent number: 9133458Abstract: It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.Type: GrantFiled: May 17, 2013Date of Patent: September 15, 2015Assignee: REPLICOR INC.Inventors: Michel Bazinet, Andrew Vaillant
-
Patent number: 8716259Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.Type: GrantFiled: May 30, 2013Date of Patent: May 6, 2014Assignee: Replicor Inc.Inventors: Andrew Vaillant, Michel Bazinet
-
Patent number: 8513211Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.Type: GrantFiled: August 18, 2011Date of Patent: August 20, 2013Assignee: Replicor Inc.Inventors: Andrew Vaillant, Michel Bazinet
-
Publication number: 20120046348Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.Type: ApplicationFiled: August 18, 2011Publication date: February 23, 2012Applicant: REPLICOR INC.Inventors: Andrew Vaillant, Michel Bazinet
-
Patent number: 8067385Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: GrantFiled: July 10, 2008Date of Patent: November 29, 2011Assignee: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Patent number: 8008270Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: GrantFiled: April 9, 2008Date of Patent: August 30, 2011Assignee: Replicor Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Patent number: 8008269Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: GrantFiled: February 28, 2008Date of Patent: August 30, 2011Assignee: Replicor Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Patent number: 7358068Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: GrantFiled: September 12, 2003Date of Patent: April 15, 2008Assignee: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Publication number: 20070123480Abstract: Randomer phosphorothioate oligonucleotide compositions have been described that inhibit PrPc conversion to PrPcs with a high level of potency. Pharmaceutical compositions or kits containing such compounds, and methods of using such compounds in the treatment, control, or prevention of prion diseases are also described.Type: ApplicationFiled: September 10, 2004Publication date: May 31, 2007Applicant: Replicor Inc.Inventors: Jean-Marc Juteau, Andrew Vaillant
-
Publication number: 20040229828Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: ApplicationFiled: September 12, 2003Publication date: November 18, 2004Applicant: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Publication number: 20040170959Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: ApplicationFiled: September 12, 2003Publication date: September 2, 2004Applicant: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Publication number: 20040171568Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: ApplicationFiled: September 12, 2003Publication date: September 2, 2004Applicant: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Publication number: 20040162253Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: ApplicationFiled: September 12, 2003Publication date: August 19, 2004Applicant: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau
-
Publication number: 20040162254Abstract: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.Type: ApplicationFiled: September 12, 2003Publication date: August 19, 2004Applicant: Replicor, Inc.Inventors: Andrew Vaillant, Jean-Marc Juteau